Protocol Number: 191622-100 07/2010 - Present Sponsor: Allergan, Inc. Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study of the Efficacy and Safety of Intraprostatic Administration of Botox® 200 U (Botulinum Toxin Type A) Purified Neurotoxin Complex to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.
Purpose of Study To access the efficacy of intraprostatic administration of Botox® 200 U compared with placebo to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
List of Completed Trials for Benign Prostatic Hyperplasia (BPH)
Protocol Number: H6D-MC-LVHK 07/2006 – 02/2008 Sponsor: Lilly, ICOS, LLC Title: A randomized, double-blind, placebo controlled, parallel design, multi-center study to evaluate the urodynamic effects of Tadalafil once a day for 12 weeks in men with signs and symptoms of Benign Prostatic Hyperplasia.
Clinical Research Coordinators: Lisa Bennett, RN or Michelle Utrera, CMA, EMT(336) 274-1114 ext. 5322 E-mail address: email@example.com